MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.070
-0.030
-0.97%
After Hours: 3.070 0 0.00% 16:10 11/10 EST
OPEN
3.070
PREV CLOSE
3.100
HIGH
3.135
LOW
2.960
VOLUME
727.18K
TURNOVER
--
52 WEEK HIGH
5.15
52 WEEK LOW
2.440
MARKET CAP
276.57M
P/E (TTM)
-3.2912
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (1102-1106)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
The Motley Fool · 4d ago
SAB Biotherapeutics Advances SAFEGUARD Enrollment, Supporting Buy Rating and $11 Price Target
TipRanks · 4d ago
SAB Biotherapeutics (SABS) Gets a Buy from Guggenheim
TipRanks · 4d ago
SAB Biotherapeutics reports Q3 EPS (24c), consensus (27c)
TipRanks · 5d ago
SAB Biotherapeutics Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
SAB Biotherapeutics reports Q3 results
Seeking Alpha · 5d ago
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.